New study reveals link between microclots and neutrophil extracellular traps in long COVID

In a groundbreaking study that shines a light on the complex pathology of long COVID, researchers have uncovered a significant structural association between microclots and neutrophil extracellular traps (NETs) in the blood of affected patients. This finding not only elucidates the underlying physiological interactions at play but also hints at potential therapeutic avenues for managing long COVID symptoms.

Microclots, a term gaining traction in medical literature, refer to abnormal aggregations of blood-clotting proteins found circulating in the bloodstream. The concept emerged in 2021, introduced by Prof Resia Pretorius from Stellenbosch University when her team detected these clots in the blood samples of COVID-19 patients. As studies during the pandemic explored their implications for various coagulopathies, microclots captured attention amid fears of prolonged illnesses associated with COVID-19.

On the other hand, neutrophil extracellular traps (NETs) are part of the body's innate immune defence. Formed during a process called NETosis, neutrophils expel DNA to form intricate structures laden with cytotoxic enzymes, which are crucial in trapping and neutralising pathogens. However, an overproduction of NETs can lead to adverse reactions and contribute to numerous health issues, from severe infections to autoimmune diseases.

In a collaborative effort led by Pretorius and Dr Alain Thierry from the Montpellier Cancer Institute, the research teams delved into the interplay between microclots and NETs within the context of long COVID. Their investigation utilised cutting-edge methods including imaging flow cytometry and fluorescence microscopy to conduct a detailed quantitative and structural comparison of these formations in the plasma of long COVID patients versus healthy controls.

The results were striking. They revealed a substantial increase in biomarkers tied to both microclots and NETs among long COVID patients, who exhibited not only a higher abundance of microclots but also significantly larger sizes. Most notably, the researchers identified a previously unreported structural association between microclots and NETs, a correlation that was present in all subjects but particularly pronounced in those with long COVID. Thierry commented, “This finding suggests the existence of underlying physiological interactions between microclots and NETs that, when dysregulated, may become pathogenic.”

To further enhance their findings, the researchers integrated artificial intelligence tools, particularly machine learning, into their biomarker analysis. This advanced approach allowed them to differentiate long COVID patients from healthy individuals with remarkable accuracy, identifying predictive biomarker combinations that could revolutionise diagnostic reliability and lead to personalised medicine solutions.

Pretorius highlighted the study's implications, noting that the pronounced accumulation of microclots in the plasma of long COVID patients is likely sustained by excessive NET production. “This interaction could render microclots more resistant to fibrinolysis, promoting their persistence in circulation and contributing to chronic microvascular complications,” she explains. By illuminating the mechanistic link between NETs and microclot stability, the research opens the door for targeted therapeutic interventions aimed at modulating thrombo-inflammatory responses in long COVID patients.

In conclusion, this study not only contributes significant insight into the pathophysiology of long COVID but also lays the groundwork for identifying novel biomarkers for diagnosis and management. The combined application of advanced imaging techniques and machine learning ensures methodological robustness, enriching the ongoing scientific discourse surrounding post-viral syndromes.